This module uses fundamental data of Can Fite to approximate its Piotroski F score. Can Fite F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Can Fite Biopharma. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Can Fite financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Can Fite Altman Z Score, Can Fite Correlation, Can Fite Valuation, as well as analyze Can Fite Alpha and Beta and Can Fite Hype Analysis.
Can
Piotroski F Score
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Net Income Per Share
Sales General And Administrative To Revenue
Average Inventory
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Price Fair Value
Return On Equity
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Total Cashflows From Investing Activities
Change To Liabilities
Sale Purchase Of Stock
Change To Operating Activities
Change To Netincome
Other Cashflows From Investing Activities
Change To Inventory
Investments
Issuance Of Capital Stock
Common Stock Shares Outstanding
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Other Liab
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Other Assets
Cash And Short Term Investments
Net Receivables
Common Stock Total Equity
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Treasury Stock
Common Stock
Property Plant Equipment
Net Tangible Assets
Non Currrent Assets Other
Inventory
Current Deferred Revenue
Capital Surpluse
Deferred Long Term Liab
Short Term Debt
Net Invested Capital
Net Working Capital
Short Term Investments
Capital Stock
Short Long Term Debt Total
Capital Lease Obligations
Depreciation And Amortization
Interest Expense
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Cost Of Revenue
Selling General Administrative
Selling And Marketing Expenses
Net Income From Continuing Ops
Net Income Applicable To Common Shares
Minority Interest
Tax Provision
Interest Income
Net Interest Income
Reconciled Depreciation
Probability Of Bankruptcy
At this time, Can Fite's Debt To Assets are most likely to slightly decrease in the upcoming years. The Can Fite's current Debt Ratio is estimated to increase to 0.01, while Short Term Debt is projected to decrease to roughly 23.1 K. At this time, Can Fite's Research And Ddevelopement To Revenue is most likely to drop in the upcoming years. The Can Fite's current Net Debt To EBITDA is estimated to increase to 0.78, while PTB Ratio is projected to decrease to 1.30.
At this time, it appears that Can Fite's Piotroski F Score is Poor. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
The critical factor to consider when applying the Piotroski F Score to Can Fite is to make sure Can is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Can Fite's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Can Fite's financial numbers are properly reported.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Can Fite's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Can Fite in a much-optimized way.
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Book Value Per Share
0.005335
At this time, Can Fite's Book Value Per Share is most likely to slightly decrease in the upcoming years.
Can Fite Current Valuation Drivers
We derive many important indicators used in calculating different scores of Can Fite from analyzing Can Fite's financial statements. These drivers represent accounts that assess Can Fite's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Can Fite's important valuation drivers and their relationship over time.
The Macroaxis Fundamental Analysis modules help investors analyze Can Fite Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Can Fite using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Can Fite Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
When determining whether Can Fite Biopharma is a strong investment it is important to analyze Can Fite's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Can Fite's future performance. For an informed investment choice regarding Can Stock, refer to the following important reports:
You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Can Fite. If investors know Can will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Can Fite listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.60)
Quarterly Revenue Growth
(0.19)
Return On Assets
(0.57)
Return On Equity
(1.58)
The market value of Can Fite Biopharma is measured differently than its book value, which is the value of Can that is recorded on the company's balance sheet. Investors also form their own opinion of Can Fite's value that differs from its market value or its book value, called intrinsic value, which is Can Fite's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Can Fite's market value can be influenced by many factors that don't directly affect Can Fite's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Can Fite's value and its price as these two are different measures arrived at by different means. Investors typically determine if Can Fite is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Can Fite's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.